Stowe Pharmaceuticals, a newly formed subsidiary of Harrow Health, has entered into an agreement with TGV Health to acquire the worldwide rights to the antimicrobial molecule Zian for ophthalmic and otic uses, according to a press release.
Zian, a patented small molecule that is water soluble, colorless and odorless, was developed to treat complex bacterial, fungal and viral infections, with its primary indication being adenoviral conjunctivitis. Secondary indications include mixed bacterial-viral infections, keratitis, endophthalmitis and corneal ulcers, the release said.
“In preclinical
Uncategorized